CoChat
Sign Up
Cited by 142

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

AAV9-mediated Expression of a Non-self Protein in Nonhuman Primate Central Nervous System Triggers Widespread Neuroinflammation Driven by Antigen-presenting Cell Transduction

Samaranch, Lluis, Sebastian, Waldy San, Kells, Adrian P, Salegio, Ernesto A, Heller, Gregory, Bringas, John R, Pivirotto, Philip, DeArmond, Stephen, Forsayeth, John, Bankiewicz, Krystof S·2014·Molecular Therapy
DOI 10.1038/mt.2013.266
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2013.266

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The above-normal increase in branching number closer to the cell body is likely the effect of the viral vector.

    “Informatively, this second effect was also observed after AAV9-GFP injections, and thus is likely the effect of the viral vector, as previously described (Mingozzi and High, 2013; Mastakov et al., 2002; Samaranch et al., 2014; Pluvinage and Wyss-Coray, 2017).”

    From The neuronal retromer can regulate both neuronal and microglial phenotypes of Alzheimer's disease (2022) · cites this paper as Samaranch et al., 2014

    The Results and Discussion describe inflammation, immune activation, and neuronal injury after AAV9-GFP delivery. Searches for branching near the cell body and AAV9-GFP effects on branching found no passage assessing branch number or attributing an increase to the viral vector. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 22

  1. Forsayeth, 2006, A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys, Mol Ther, 14, 571, 10.1016/j.ymthe.2006.04.008 · DOI
  2. Haurigot, 2013, Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy, J Clin Invest, 123, 3254, 10.1172/JCI66778 · DOI · Paper page
  3. Ciesielska, 2013, Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses, Mol Ther, 21, 158, 10.1038/mt.2012.167 · DOI · Paper page
  4. Hadaczek, 2009, Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response, Hum Gene Ther, 20, 225, 10.1089/hum.2008.151 · DOI · Paper page
  5. Bankiewicz, 2000, Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach, Exp Neurol, 164, 2, 10.1006/exnr.2000.7408 · DOI
  6. Bobo, 1994, Convection-enhanced delivery of macromolecules in the brain, Proc Natl Acad Sci USA, 91, 2076, 10.1073/pnas.91.6.2076 · DOI
  7. Bartlett, 1998, Selective and rapid uptake of adeno-associated virus type 2 in brain, Hum Gene Ther, 9, 1181, 10.1089/hum.1998.9.8-1181 · DOI
  8. Ciesielska, 2009, Anterograde axonal transport of AAV2-GDNF in rat basal ganglia, Molecular Therapy, 1
  9. Samaranch, 2013, Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates, Hum Gene Ther, 24, 526, 10.1089/hum.2013.005 · DOI
  10. Barski, 2003, Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination, J Neurosci, 23, 3469, 10.1523/JNEUROSCI.23-08-03469.2003 · DOI
  11. Aalbers, 2011, Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon, F1000 Med Rep, 3, 17, 10.3410/M3-17 · DOI
  12. Manning, 1998, Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors, Hum Gene Ther, 9, 477, 10.1089/hum.1998.9.4-477 · DOI · Paper page
  13. Treleaven, 2012, Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies, Mol Ther, 20, 1713, 10.1038/mt.2012.114 · DOI · Paper page
  14. Dodiya, 2010, Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates, Mol Ther, 18, 579, 10.1038/mt.2009.216 · DOI · Paper page
  15. McBride, 2011, Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease, Mol Ther, 19, 2152, 10.1038/mt.2011.219 · DOI · Paper page
  16. Klein, 2006, Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins, Mol Ther, 13, 517, 10.1016/j.ymthe.2005.10.008 · DOI · Paper page
  17. Gray, 2011, Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors, Hum Gene Ther, 22, 1143, 10.1089/hum.2010.245 · DOI · Paper page
  18. Bevan, 2011, Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol Ther, 19, 1971, 10.1038/mt.2011.157 · DOI · Paper page
  19. Matsushita, 1998, Adeno-associated virus vectors can be efficiently produced without helper virus, Gene Ther, 5, 938, 10.1038/sj.gt.3300680 · DOI
  20. Wright, 2003, Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector, Curr Opin Drug Discov Devel, 6, 174
  21. Fiandaca, 2008, Image-guided convection-enhanced delivery platform in the treatment of neurological diseases, Neurotherapeutics, 5, 123, 10.1016/j.nurt.2007.10.064 · DOI
  22. Krauze, 2005, Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents, J Neurosurg, 103, 923, 10.3171/jns.2005.103.5.0923 · DOI

Cited by

Sorted by citations

Metadata

Authors
Samaranch, L., Sebastian, W. S., Kells, A. P., Salegio, E. A., Heller, G., Bringas, J. R., Pivirotto, P., DeArmond, S., Forsayeth, J., & Bankiewicz, K. S.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2014-02
Volume
22
Issue
2
Pages
329-337
ISSN
1525-0016
DOI
10.1038/mt.2013.266
Cited by
142
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review